BOT 1.45% 34.0¢ botanix pharmaceuticals ltd

Ann: FDA Approves Sofdra, page-286

  1. 268 Posts.
    lightbulb Created with Sketch. 103
    I see that some are pointing to DXB as a comparison, (I used to be in DXB, but made my money and got out) but DXB, while it has an awesome and important product, doesn't have:
    phase 3 trial results;
    FDA approval;
    A product that is already selling in another jurisdiction;
    strong sales results there;
    a sales team and support network ready to go and primed for success.
    DXB does have Nina, and she is brilliant.
    BOT, as I have said before, will paddle its own canoe.
    The CR may be an inconvenience for some, but it is seriously only a blip, but it is, as has been pointed out by others, an important step in maximising any return from any buyout that may appear on the horizon.
 
watchlist Created with Sketch. Add BOT (ASX) to my watchlist
(20min delay)
Last
34.0¢
Change
-0.005(1.45%)
Mkt cap ! $615.4M
Open High Low Value Volume
34.0¢ 34.0¢ 32.8¢ $1.949M 5.840M

Buyers (Bids)

No. Vol. Price($)
1 2985 33.5¢
 

Sellers (Offers)

Price($) Vol. No.
34.0¢ 420471 4
View Market Depth
Last trade - 16.10pm 05/07/2024 (20 minute delay) ?
BOT (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.